Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

European regulators on Friday upheld its negative opinion on Apellis Pharmaceuticals' (NASDAQ:APLS) proposed treatment for ...

Apellis Pharmaceuticals, Inc. (APLS) announced on Friday that the Committee for Medicinal Products for Human Use or CHMP of the ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shares are moving lower Friday after the Committee for Medicinal Products for ...

This CHMP opinion was made despite broad support for pegcetacoplan from the European retina community and multiple dissenting votes by CHMP members who supported a path to approval.” “We have seen the ...

The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able ...

Apellis has said it will seek a re-examination of the CHMP’s opinion, noting that there were “multiple dissenting voices” by members of the panel. It also said that specialists at an ad hoc ...

Apellis said it was expecting the CHMP’s decision after the panel indicated it was minded to reject the application in December and added that it would seek “immediate re-examination” of the ...

Aug. 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals ... from the Committee for Medicinal Products for Human Use (CHMP) received in June 2024. There were multiple dissenting votes to ...

The firm's stance comes ahead of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) expected final opinion on the approval of Apellis's drug pegcetacoplan ...

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases ...

Mizuho has reiterated its Neutral rating on Apellis Pharmaceuticals (NASDAQ: NASDAQ:APLS) with a steady price target of $42.00. The firm's stance comes ahead of the European Medicines Agency's (EMA) ...